Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2021
Reporting Period: The filing reports on a material definitive agreement entered into on April 20, 2021, regarding a private placement financing transaction.
Key Financial Metrics and Transaction Details
This filing details a financing arrangement rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Debt Instrument: Future advance convertible promissory note with an aggregate principal amount of up to $3,402,000.
- Initial Disbursement: $750,000 advanced on April 21, 2021.
- Interest Rate: 5% per annum.
- Maturity: 12 months from the date of issuance.
- Equity Component: Warrant to purchase 16,666,667 shares of common stock.
- Warrant Terms: Exercise price of $0.18 per share; four-year term.
- Conversion Price: Lesser of $0.18 or 90% of the closing price on the effective date of the Registration Statement.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement with Leviston Resources, LLC. Key structural elements include:
- Subordination: The rights of the new purchaser (Leviston) are subordinate to the rights of NH Expansion Credit Fund Holdings LP ("North Haven Expansion") pursuant to a Subordination Agreement.
- Security: The Company agreed to enter into a Security Agreement to secure obligations under the Note prior to any disbursements after the initial one.
- Registration Rights: The Company agreed to file a registration statement within 30 days of the closing date to register 100% of shares issuable upon conversion of the Note and exercise of the Warrants.
Outlook, Risks, and Contingencies
Contingencies: Remaining disbursements up to the aggregate amount of $3,402,000 are subject to the satisfaction of certain terms and conditions set forth in the Note. The filing does not specify these conditions.
Risks: The Note contains customary events of default and covenants, including limitations on the incurrence of additional indebtedness and liens. The transaction was conducted as a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
Management Commentary: The filing incorporates by reference a press release dated April 28, 2021, but does not contain direct management commentary within the text of the 8-K itself.
Investor Verification Checklist
- Verify the specific terms and conditions required for the remaining disbursements of the $3,402,000 note.
- Review the full text of the Subordination Agreement (Exhibit 10.2) to understand the priority of claims relative to North Haven Expansion.
- Confirm the status of the Registration Statement filing required within 30 days of the closing date.
- Assess the impact of the warrant exercise price ($0.18) and conversion price on potential future dilution.
- Check for any subsequent filings regarding the satisfaction of covenants or events of default.